CKPT
vs
S&P 500
CKPT
S&P 500
Over the past 12 months, CKPT has outperformed S&P 500, delivering a return of +32% compared to the S&P 500's +14% growth.
Stocks Performance
CKPT vs S&P 500
Performance Gap
CKPT vs S&P 500
Performance By Year
CKPT vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Checkpoint Therapeutics Inc
Glance View
Checkpoint Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company is headquartered in New York City, New York and currently employs 14 full-time employees. The company went IPO on 2016-11-02. The firm is evaluating its lead antibody product candidate, cosibelimab, which is an anti-programmed death-ligand 1 (PD-L1) antibody licensed from the Dana-Farber Cancer Institute (Dana-Farber) in an ongoing global, open-label, multicohort Phase I clinical trial in checkpoint therapy-naive patients with selected recurrent or metastatic cancers, including ongoing cohorts in locally advanced and metastatic cutaneous squamous cell carcinoma (CSCC) intended to support one or more applications for marketing approval. In addition, it is evaluating its lead small-molecule, targeted anti-cancer agent, CK-101, which is an epidermal growth factor receptor (EGFR) inhibitor as a treatment for patients with EGFR mutation-positive non-small cell lung cancer (NSCLC).
